# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN
- Date: 2026-08-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Test of cure for hepatitis C and six-month liver cancer surveillance. **S**

## History of present illness

Mr. Knievel returns 13 weeks after his last dose of sofosbuvir-velpatasvir. The surveillance ultrasound a week ago showed no liver lesion. He had the zoledronic acid infusion eleven weeks ago, with a day of aches afterwards. His eye examination in June showed no diabetic retinopathy. He has had no alcohol since February. He takes carvedilol 12.5 mg daily. Pain is about 4 of 10 and he walks 30 minutes most days. He has had no falls, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Cure | HCV RNA not detected 13 weeks after treatment |
| Surveillance | Ultrasound a week ago: no lesion; alpha-fetoprotein 3.4 ng/mL |
| Liver function | Child-Pugh A5; MELD-Na 6 |
| Bone | Zoledronic acid given eleven weeks ago |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight steady |
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting of blood |
| Musculoskeletal | Positive | Hip and knee pain, 4 of 10 |
| Neurological | Negative | No confusion or tremor |
| Endocrine | Negative | No low glucose readings |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day **S**
- Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day **S**
- Carvedilol 12.5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily **S**
- Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a year **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 82.6 kg; BMI 26.1 kg/m². All vital signs are synthetic.

Hemoglobin: 14.4 g/dL; White cell count: 5.2 10*3/uL; Platelets: 134 10*3/uL (low); Creatinine: 0.88 mg/dL; eGFR (CKD-EPI 2021): 100 mL/min/1.73 m²; Glucose (fasting): 112 mg/dL (high); ALT: 22 U/L; AST: 26 U/L; Alkaline phosphatase: 92 U/L; Total bilirubin: 0.8 mg/dL; Albumin: 4 g/dL; INR: 1; HCV RNA (quantitative): 0 [IU]/mL; Alpha-fetoprotein: 3.4 ng/mL; Hemoglobin A1c: 6.3% (high); Glucose management indicator (14-day CGM): 6.8%; AUDIT-C: 0; PHQ-9: 3; Pain (0 to 10): 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.9 g/dL at baseline, 14.4 g/dL at this visit **S**
- White cell count: 4.6 10*3/uL at baseline, 5.2 10*3/uL at this visit **S**
- Platelets: 118 10*3/uL (low) at baseline, 134 10*3/uL (low) at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.88 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 97 mL/min/1.73 m² at baseline, 100 mL/min/1.73 m² at this visit **S**
- Glucose (fasting): 162 mg/dL (high) at baseline, 112 mg/dL (high) at this visit **S**
- ALT: 88 U/L (high) at baseline, 22 U/L at this visit **S**
- AST: 96 U/L (high) at baseline, 26 U/L at this visit **S**
- Alkaline phosphatase: 104 U/L at baseline, 92 U/L at this visit **S**
- Total bilirubin: 1.1 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 4 g/dL at this visit **S**
- INR: 1.1 at baseline, 1 at this visit **S**
- Hemoglobin A1c: 7.4% (high) at baseline, 6.3% (high) at this visit **S**
- AUDIT-C: 7 at baseline, 0 at this visit **S**
- Pain (0 to 10): 7 at baseline, 4 at this visit **S**

## Immunizations given today

- Hepatitis A vaccine, adult, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 82.6 kg; blood pressure 120/74, pulse 60 |
| Skin | A few spider angiomas; no jaundice |
| Abdomen | Spleen tip palpable; no ascites |
| Neurological | No asterixis; gait steady |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic hepatitis C, cured (sustained virologic response)** (B18.2). HCV RNA not detected 13 weeks after a 12-week course, with ALT 22 and AST 26 U/L: virologic and biochemical cure. The antibody will stay positive for life, so any future check for reinfection must be an HCV RNA test. **S**
   - Problem resolved.
   - HCV RNA if liver tests rise or a new exposure occurs.
2. **Compensated cirrhosis after cure** (K74.69). Child-Pugh A5 (bilirubin 0.8 mg/dL, albumin 4.0 g/dL, INR 1.0) and MELD-Na 6; platelets 134, rising; FIB-4 now 2.36. Cure lowers but does not remove the risk of liver cancer and decompensation in cirrhosis. No transplant evaluation: there has been no decompensation and the MELD-Na is far below 15. **S**
   - Ultrasound with alpha-fetoprotein every six months for life; next in February.
   - Liver stiffness and platelets a year after cure, to see whether portal hypertension has improved.
   - No alcohol.
3. **Clinically significant portal hypertension** (K76.6). Continue carvedilol until reassessment a year after cure. **S**
   - Carvedilol 12.5 mg daily.
4. **Type 2 diabetes** (E11.65). Glucose management indicator 6.8%, A1c 6.3%, fasting glucose 112 mg/dL; no hypoglycemia; no retinopathy. **S**
   - Continue metformin and the sensor.
5. **Osteoporosis** (M81.8). Zoledronic acid given; no falls. **S**
   - Next infusion in nine months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HCV RNA 12 or more weeks after treatment (SVR12) | Once, 12 or more weeks after the last dose | Completed today | Not detected: cured |
| Laboratory | Hepatic function panel after treatment | With the test of cure | Completed today | ALT 22, AST 26, alkaline phosphatase 92 U/L, bilirubin 0.8 mg/dL, albumin 4.0 g/dL |
| Laboratory | Blood count, INR and kidney function in cirrhosis | Every six months | Completed today | Platelets 134, hemoglobin 14.4 g/dL, white cells 5.2; INR 1.0; creatinine 0.88 mg/dL, eGFR 100 |
| Examination | Child-Pugh class and MELD-Na | Every six months in cirrhosis | Completed today | Child-Pugh A5; MELD-Na 6 |
| Imaging | Liver ultrasound for cancer surveillance at six months | Every six months in cirrhosis | Deferred | A deviation: due six months after the baseline scan, in July, but done a week ago, about three weeks late, because the recall was set from the hepatology visit and then held until after the test of cure. No harm resulted: no lesion (LI-RADS US-1). Corrective action: the recall is now set from the date of each scan, every six months |
| Laboratory | Alpha-fetoprotein with surveillance ultrasound | Every six months with ultrasound | Completed today | 3.4 ng/mL |
| Imaging | Next surveillance ultrasound with alpha-fetoprotein | Every six months | Due | February |
| Imaging | Liver stiffness after cure | A year after cure (Baveno VII) | Due | Next summer, with hepatology |
| Referral | Liver transplant evaluation | With decompensation or MELD-Na of 15 or more | Not indicated | Compensated; MELD-Na 6 |
| Medication safety | Hepatitis A vaccination, dose 2 | Six months or more after dose 1 | Completed today | Given today; series complete |
| Laboratory | Glucose control: A1c with sensor data | Every three months when therapy changes | Completed today | A1c 6.3%; glucose management indicator 6.8%; fasting glucose 112 mg/dL |
| Referral | Diabetic eye examination | Yearly | Up to date | Done in June: no retinopathy |
| Medication safety | Zoledronic acid | Yearly | Up to date | Given eleven weeks ago; next in nine months, after a calcium check |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Self-management | Falls and fracture risk | Each visit | Completed today | No falls |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 0 |
| Survey | Pain score and function | Each visit | Completed today | 4 of 10; walking 30 minutes |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 3 |

## Goal progress

- Hepatitis C confirmed or excluded and liver disease staged within three weeks. Outcome by 2026-01-26: Chronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks. **S**
- Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment. Outcome by 2026-08-17: HCV RNA not detected 13 weeks after a 12-week course. **S**
- No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 15. Outcome by 2026-08-17: No decompensation; Child-Pugh A5; MELD-Na 6 after cure. **S**
- No alcohol. Outcome by 2026-08-17: No alcohol since the start of antiviral treatment; AUDIT-C 0. **S**
- Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids. Outcome by 2026-08-17: Pain 4 of 10; walking 30 minutes in the pool and on flat ground; no NSAIDs or opioids. **S**
- Glucose management indicator below 7% without hypoglycemia. Outcome by 2026-08-17: Glucose management indicator 6.8%; no hypoglycemia. **S**
- Vitamin D replete and osteoporosis treatment started; no falls with injury. Outcome by 2026-08-17: Vitamin D 34 ng/mL; zoledronic acid given; no further falls. **S**

## Guideline basis

- AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023), American Association for the Study of Liver Diseases
- de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022), Baveno VII Faculty (Journal of Hepatology)
- Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024), American Association for the Study of Liver Diseases
- Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021), American Association for the Study of Liver Diseases
- Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019), American Association for the Study of Liver Diseases
- Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018), American Association for the Study of Liver Diseases (Clinical Liver Disease)
- Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022), Centers for Disease Control and Prevention
- American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026), American Diabetes Association
- American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026), American Diabetes Association
- Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012), Endocrine Society
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit next month. Ultrasound with alpha-fetoprotein in February. Hepatology review with liver stiffness a year after cure. Call for abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. **S**
- Next scheduled visit 2026-09-21: periodic adult preventive visit. **S**
